nemvaleukin – Patient Worthy

https://unsplash.com/photos/In4XVKhYaiI

Nemvaleukin Alfa Granted Orphan Drug Status for Mucosal Melanoma

Post author:Jessica Lynn
Post published:March 12, 2021
Post category:Melanoma

On March 11, 2021, global biopharmaceutical company Alkermes plc shared that its investigational drug candidate nemvaleukin alfa received Orphan Drug designation from the FDA. The treatment is designed for patients…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More